{
  "trial_id": "NCT02858895",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, Karnofsky Performance Score (KPS), tumor size, tumor location, prior treatments, time since last treatment, presence of IDH1/IDH2 mutation, life expectancy, MRI findings, comorbid conditions, history of allergies, HIV status, concurrent medical illnesses, previous malignancies.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Karnofsky Performance Score (KPS)",
          "Karnofsky Performance Score (KPS)"
        ],
        [
          "Prior Glioblastoma treatment",
          "prior treatments"
        ],
        [
          "Maximum tumor diameter at baseline",
          "tumor size"
        ],
        [
          "Diagnostic method of Glioblastoma",
          "MRI findings"
        ],
        [
          "Known mutation in either the isocitrate dehydrogenase 1 (IDH1) or the IDH2 gene",
          "presence of IDH1/IDH2 mutation"
        ],
        [
          "Life expectancy",
          "life expectancy"
        ],
        [
          "Concurrent or a history of any significant medical illnesses",
          "concurrent medical illnesses"
        ],
        [
          "Known history of allergy to gadolinium contrast agents",
          "history of allergies"
        ],
        [
          "Known to be human immunodeficiency virus positive",
          "HIV status"
        ],
        [
          "Presence of another type of malignancy requiring treatment within < 3 years prior to the screening visit",
          "previous malignancies"
        ]
      ],
      "remaining_reference_features": [
        "Race/Ethnicity",
        "Ethnicity",
        "o6-methylguanine-DNA-methyltransferase (MGMT) Status",
        "Steroid Use",
        "Initial diagnosis to 1st relapse",
        "Max tumor diameter at initial diagnosis",
        "Number of prior relapse",
        "Tumor volume at baseline",
        "Lymphocyte Count"
      ],
      "remaining_candidate_features": [
        "tumor location",
        "time since last treatment",
        "comorbid conditions"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Karnofsky Performance Score (KPS), Tumor Size, Number of Prior Recurrences, Prior Treatments, Time Since Initial Diagnosis,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Karnofsky Performance Score (KPS)",
          "Karnofsky Performance Score (KPS)"
        ],
        [
          "Number of prior relapse",
          "Number of Prior Recurrences"
        ],
        [
          "Prior Glioblastoma treatment",
          "Prior Treatments"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity",
        "o6-methylguanine-DNA-methyltransferase (MGMT) Status",
        "Steroid Use",
        "Diagnostic method of Glioblastoma",
        "Initial diagnosis to 1st relapse",
        "Max tumor diameter at initial diagnosis",
        "Tumor volume at baseline",
        "Maximum tumor diameter at baseline",
        "Lymphocyte Count"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "Tumor Size",
        "Time Since Initial Diagnosis"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Karnofsky Performance Score, Histological diagnosis of glioblastoma, Tumor size, Tumor location, Prior treatments for glioblastoma, Time since initial diagnosis, Time since last recurrence, IDH1/2 mutation status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Karnofsky Performance Score (KPS)",
          "Karnofsky Performance Score"
        ],
        [
          "Diagnostic method of Glioblastoma",
          "Histological diagnosis of glioblastoma"
        ],
        [
          "Prior Glioblastoma treatment",
          "Prior treatments for glioblastoma"
        ],
        [
          "Initial diagnosis to 1st relapse",
          "Time since initial diagnosis"
        ],
        [
          "IDH1/2 mutation status",
          "IDH1/2 mutation status"
        ]
      ],
      "remaining_reference_features": [
        "Race/Ethnicity",
        "Ethnicity",
        "o6-methylguanine-DNA-methyltransferase (MGMT) Status",
        "Steroid Use",
        "Max tumor diameter at initial diagnosis",
        "Number of prior relapse",
        "Tumor volume at baseline",
        "Maximum tumor diameter at baseline",
        "Lymphocyte Count"
      ],
      "remaining_candidate_features": [
        "Tumor size",
        "Tumor location",
        "Time since last recurrence"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, Karnofsky Performance Score (KPS), life expectancy, tumor size, tumor location, number of recurrences, time since initial diagnosis, time since last recurrence, prior treatments, IDH1/2 mutation status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Karnofsky Performance Score (KPS)",
          "Karnofsky Performance Score (KPS)"
        ],
        [
          "Number of prior relapse",
          "number of recurrences"
        ],
        [
          "Initial diagnosis to 1st relapse",
          "time since initial diagnosis"
        ],
        [
          "Prior Glioblastoma treatment",
          "prior treatments"
        ],
        [
          "Maximum tumor diameter at baseline",
          "tumor size"
        ],
        [
          "IDH1/2 mutation status",
          "IDH1/2 mutation status"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race/Ethnicity",
        "Ethnicity",
        "o6-methylguanine-DNA-methyltransferase (MGMT) Status",
        "Steroid Use",
        "Diagnostic method of Glioblastoma",
        "Max tumor diameter at initial diagnosis",
        "Tumor volume at baseline",
        "Lymphocyte Count"
      ],
      "remaining_candidate_features": [
        "life expectancy",
        "tumor location",
        "time since last recurrence"
      ]
    }
  }
}